About ICM-502

ICM-502 is a gene therapy product designed to express canine target genes based on our osteoarthritis targerting ICM-203. Using the same ROA of ICM-203, it is intra-articularly injected to minimize the risk of off-target exposure, allowing the therapeutic gene to be expressed specifically in the target cells of osteoarthritis. Currently, ICM-502 is undergoing validation of therapeutic gene expression and non-GLP toxicity and biodistribution studies using healthy large dogs. We are also preparing for GLP toxicology studies and the production of investigational products for veterinary use.